Fig. 3From: Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the NetherlandsCost-effectiveness acceptability curve of the discounted model analysis. BSC, best supportive care; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yearBack to article page